Citation Impact
Citing Papers
An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101
2015
Randomized Phase II Study of Gemcitabine and Docetaxel Compared With Gemcitabine Alone in Patients With Metastatic Soft Tissue Sarcomas: Results of Sarcoma Alliance for Research Through Collaboration Study 002
2007
Phase II Study of Ecteinascidin-743 in Advanced Pretreated Soft Tissue Sarcoma Patients
2004
Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial
2015
PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors
2003 StandoutScience
Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data
1997 Standout
Hypoxia Response Elements in the Aldolase A, Enolase 1, and Lactate Dehydrogenase A Gene Promoters Contain Essential Binding Sites for Hypoxia-inducible Factor 1
1996 StandoutNobel
Soft Tissue Leiomyosarcomas and Malignant Gastrointestinal Stromal Tumors: Differences in Clinical Outcome and Expression of Multidrug Resistance Proteins
2000
Nasopharyngeal carcinoma
2005 Standout
Phase III trial of standard versus dose-intensified doxorubicin, ifosfamide and dacarbazine (MAID) in the first-line treatment of metastatic and locally advanced soft tissue sarcoma
2009
Suppression of tumor growth through disruption of hypoxia-inducible transcription
2000 StandoutNobel
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial
2009 Standout
Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: A Gynecologic Oncology Group phase II study
2008
Perspectives on cancer therapy-induced mucosal injury
2004 Standout
Results of Two Consecutive Trials of Dose-Intensive Chemotherapy With Doxorubicin and Ifosfamide in Patients With Sarcomas
1998
Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome
2007 StandoutNobel
Cell Signaling by Receptor Tyrosine Kinases
2010 Standout
Un Ménage à Quatre
2003
ERS/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and chemo-radiotherapy)
2009 Standout
Soft Tissue Sarcomas
2004
Effect of the Tyrosine Kinase Inhibitor STI571 in a Patient with a Metastatic Gastrointestinal Stromal Tumor
2001 Standout
Molecular characterisation of soft tissue tumours: a gene expression study
2002 Standout
A phase II study of ifosfamide, 5-fluorouracil and leucovorin in patients with recurrent nasopharyngeal carcinoma previously treated with platinum chemotherapy
2000
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
2008 Standout
The phosphatidylinositol 3-Kinase–AKT pathway in human cancer
2002 Standout
Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: A Gynecologic Oncology Group phase II trial
2008
Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial
2002 Standout
High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas.
1995
Clinical management of gastrointestinal stromal tumors: Before and after STI-571
2002
Primary Extremity Sarcoma: What Is the Appropriate Follow-Up?
2000
HIF-1α Induces Genetic Instability by Transcriptionally Downregulating MutSα Expression
2005 StandoutNobel
Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study
2010
Soft-Tissue Sarcomas in Adults
2005 Standout
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial
2006 Standout
Intensified Adjuvant IFADIC Chemotherapy for Adult Soft Tissue Sarcoma: A Prospective Randomized Feasibility Trial
2000
A systematic meta‐analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft‐tissue sarcoma
2008 Standout
Long-term results of a multicenter SAKK trial on high-dose ifosfamide and doxorubicin in advanced or metastatic gynecologic sarcomas
2006
Dose-intensive chemotherapy with ifosfamide, epirubicin, and filgrastim for adult patients with metastatic or locally advanced soft tissue sarcoma: a phase II study.
1998
An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas.
1993
The human cumulus–oocyte complex gene-expression profile
2006
Lung cancer: current therapies and new targeted treatments
2016 Standout
Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients
2002
Dose‐intensive chemotherapy with growth factor or autologous bone marrow/stem cell transplant support in first‐line treatment of advanced or metastatic adult soft tissue sarcoma
2008
Adjuvant chemotherapy for soft-tissue sarcoma: review and meta-analysis of the published results of randomised clinical trials
1995
Alveolar rhabdomyosarcomas in conditional Pax3:Fkhr mice: cooperativity of Ink4a/ARF and Trp53 loss of function
2004 StandoutNobel
A comparison of staging systems for localized extremity soft tissue sarcoma
2000
Effect of adjuvant chemotherapy on time to recurrence and survival of stage I uterine sarcomas
1988
Oxygen sensing and hypoxia signalling pathways in animals: the implications of physiology for cancer
2013 StandoutNobel
Levels of Hypoxia-Inducible Factor-1 During Breast Carcinogenesis
2001 StandoutNobel
Adjuvant Chemotherapy for Gastric Cancer with S-1, an Oral Fluoropyrimidine
2007 Standout
Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas
2002
Chemotherapy-Induced Nausea and Vomiting
2008 Standout
Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial
2004 Standout
Fine needle aspiration (FNA) cytology in the diagnosis of recurrent soft tissue sarcoma
1998
Chemotherapy Is Associated With Improved Survival in Adult Patients With Primary Extremity Synovial Sarcoma
2007
Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasone
2010
Hereditary Colorectal Cancer
2003 Standout
Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL®/CAELYX®) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma
2001
Hyperthermia adds to chemotherapy
2008
Soft Tissue Sarcoma: An Update on Systemic Treatment Options for Patients with Advanced Disease
2014
Use of doxorubicin and dacarbazine for the management of unresectable intra-abdominal desmoid tumors in Gardner's syndrome
1994
Synovial sarcoma: A retrospective analysis of 271 patients of all ages treated at a single institution
2004
High-dose chemotherapy consolidation for chemosensitive advanced soft tissue sarcoma patients: an open-label, randomized controlled trial
2011
Meta-analysis of ifosfamide-based combination chemotherapy in advanced soft tissue sarcoma
2008
Ifosfamide in the Adjuvant Therapy of Soft Tissue Sarcomas
2003
Multiple-Treatments Meta-analysis of Chemotherapy and Targeted Therapies in Advanced Breast Cancer
2008
Advanced soft-tissue sarcoma: a disease that is potentially curable for a subset of patients treated with chemotherapy
2002
Randomized Clinical Trials in Soft Tissue Sarcoma
2002
Adjuvant Epirubicin With or Without Ifosfamide for Adult Soft-Tissue Sarcoma
2002
Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas
2009
Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study
2001
Gemcitabine in advanced adult soft-tissue sarcomas. A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group
2002
Significant clinical benefit of first‐line palliative chemotherapy in advanced soft‐tissue sarcoma
2008
Pulmonary Metastases From Soft Tissue Sarcoma
1999
Quantifying heterogeneity in a meta‐analysis
2002 Standout
The role of pulmonary metastasectomy in soft tissue sarcoma
2002
Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial
2012 Standout
Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial
2016 Standout
Effect of high-dose ifosfamide in advanced soft tissue sarcomas. A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group
2000
Phase II Study of S-1, a Novel Oral Derivative of 5-Fluorouracil, in Advanced Gastric Cancer
2000
HIF and the Lung
2011 StandoutNobel
Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease
2012 Standout
HIF-1: mediator of physiological and pathophysiological responses to hypoxia
2000 StandoutNobel
Gemcitabine and Docetaxel in Patients With Unresectable Leiomyosarcoma: Results of a Phase II Trial
2002
Phase II Study of ET-743 in Advanced Soft Tissue Sarcomas: A European Organisation for the Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group Trial
2005 Standout
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial
2014 Standout
Randomized Phase II Evaluation of 6 g/m2 of Ifosfamide Plus Doxorubicin and Granulocyte Colony-Stimulating Factor (G-CSF) Compared With 12 g/m2 of Ifosfamide Plus Doxorubicin and G-CSF in the Treatment of Poor-Prognosis Soft Tissue Sarcoma
2004
Phase II Trial of Weekly Paclitaxel for Unresectable Angiosarcoma: The ANGIOTAX Study
2008
Molecular Pathobiology of Gastrointestinal Stromal Sarcomas
2008
Degradable Controlled-Release Polymers and Polymeric Nanoparticles: Mechanisms of Controlling Drug Release
2016 Standout
Efficacy of Sequential High-Dose Doxorubicin and Ifosfamide Compared With Standard-Dose Doxorubicin in Patients With Advanced Soft Tissue Sarcoma: An Open-Label Randomized Phase II Study of the Spanish Group for Research on Sarcomas
2009
The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations
2015 Standout
Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma.
1996 Standout
Randomized Phase III Study Comparing Conventional-Dose Doxorubicin Plus Ifosfamide Versus High-Dose Doxorubicin Plus Ifosfamide Plus Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor in Advanced Soft Tissue Sarcomas: A Trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group
2000
Proposal for classifying the acute emetogenicity of cancer chemotherapy.
1997 Standout
Adjuvant Chemotherapy for Soft Tissue Sarcomas
1991
Structure, Recognition, and Processing of Cisplatin−DNA Adducts
1999 Standout
The Protein Kinase C Agonist PEP005 (Ingenol 3-Angelate) in the Treatment of Human Cancer: A Balance between Efficacy and Toxicity
2010
Ecteinascidin-743: A Marine-Derived Compound in Advanced, Pretreated Sarcoma Patients—Preliminary Evidence of Activity
2001
Adjuvant Therapy Of Soft-Tissue Sarcomas
1995
Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth
1997 StandoutNobel
The treatment of soft tissue sarcomas with focus on chemotherapy: A review
1986
Adjuvant Chemotherapy for Adult Soft Tissue Sarcomas of the Extremities and Girdles: Results of the Italian Randomized Cooperative Trial
2001
Adjuvant Chemotherapy for Soft Tissue Sarcomas
1995
Regulation of Mammalian O2Homeostasis by Hypoxia-Inducible Factor 1
1999 StandoutNobel
DNA Double-Strand Breaks
2002 StandoutNobel
HMG-domain proteins specifically inhibit the repair of the major DNA adduct of the anticancer drug cisplatin by human excision nuclease.
1994 StandoutNobel
Imatinib mesylate (STI-571 Glivec®, Gleevec™) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target
2003
Euphorbia Diterpenes: Isolation, Structure, Biological Activity, and Synthesis (2008–2012)
2014 Standout
Primary Adult Soft Tissue Sarcoma: Time-Dependent Influence of Prognostic Variables
2002
Photopharmacology: Beyond Proof of Principle
2014 StandoutNobel
Long-term results of lung metastasectomy: Prognostic analyses based on 5206 cases
1997 Standout
Cisplatin
1984 Standout
Works of J. Buesa being referenced
Randomized Phase II Study Comparing Gemcitabine Plus Dacarbazine Versus Dacarbazine Alone in Patients With Previously Treated Soft Tissue Sarcoma: A Spanish Group for Research on Sarcomas Study
2011
Randomized Phase II Study of Docetaxel versus Doxorubicin in first- and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults: A Study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
2000
A randomised phase II study on neo-adjuvant chemotherapy for ‘high-risk’ adult soft-tissue sarcoma
2001
High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC soft tissue and bone sarcoma group
1998
Doxorubicin in relapsed soft tissue sarcoma: Justification of phase II evaluation of new drugs in this disease
1990
Phase II Trial of Doxorubicin Plus Escalated High‐Dose Ifosfamide in Patients With Advanced Soft Tissue Sarcomas of the Adult: A Study of the Spanish Group for Research on Sarcomas (GEIS)
2006
Salvage surgical resection after high‐dose ifosfamide (HDIF) based regimens in advanced soft tissue sarcoma (ASTS): A potential positive selection bias—A study of the Spanish Group for Research on Sarcomas (GEIS)
2004
Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
1995
Chemotherapy in the multidisciplinary approach to soft tissue sarcomas
1992
Phase II trial of first-line high-dose ifosfamide in advanced soft tissue sarcomas of the adult: A study of the Spanish Group for Research on Sarcomas (GEIS)
1998
A phase II trial of temozolomide as a 6‐week, continuous, oral schedule in patients with advanced soft tissue sarcoma
2005
Phase II trial of ifosfamide in recurrent and metastatic head and neck cancer
1991
Temozolomide in adult patients with advanced soft tissue sarcoma: a phase II study of the EORTC Soft Tissue and Bone Sarcoma Group
1999
Sequential dose‐dense doxorubicin and ifosfamide for advanced soft tissue sarcomas
2004
Adjuvant CYVADIC chemotherapy for adult soft tissue sarcoma--reduced local recurrence but no improvement in survival: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
1994
Pulmonary toxicity in patients treated with gemcitabine plus vinorelbine or docetaxel for advanced non-small cell lung cancer: outcome data on a randomized phase II study
2007
High-dose DTIC in advanced soft-tissue sarcomas in the adult
1991
Adriamycin versus epirubicin in advanced soft tissue sarcomas. A randomized phase II/phase III study of the EORTC soft tissue and bone sarcoma group
1987
Combination chemotherapy with cisplatin and 5-fluorouracil 5-day infusion in the therapy of advanced gastric cancer: A Phase II trial
1991
Cohesin component dynamics during meiotic prophase I in mammalian oocytes
2004
STAG2 and Rad21 mammalian mitotic cohesins are implicated in meiosis
2002
Cyvadic in advanced soft tissue sarcoma: A randomized study comparing two schedules: A study of the EORTC soft tissue and bone sarcoma group
1984
Prognostic Factors for the Outcome of Chemotherapy in Advanced Soft Tissue Sarcoma: An Analysis of 2,185 Patients Treated With Anthracycline-Containing First-Line Regimens—A European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study
1999
Fine needle aspiration cytology of soft-tissue lesions.
1987
Randomized Phase II Study of Docetaxel Versus Doxorubicin in First- and Second-Line Chemotherapy for Locally Advanced or Metastatic Soft Tissue Sarcomas in Adults: A Study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group
2000
Phase III trial of cyclophosphamide, epirubicin, fluorouracil (CEF) versus cyclophosphamide, mitoxantrone, fluorouracil (CNF) in women with metastatic breast cancer
1999
Surgical treatment of lung metastases: The European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group study of 255 patients
1996
Treatment of advanced soft tissue sarcomas with low-dose methotrexate: a phase II trial by the European Organization of Research on Treatment for Cancer (EORTC) Soft Tissue and Bone Sarcoma Group.
1984
Phase II clinical trial of cis-dichlorodiammineplatinum in gastric cancer
1983
Deletions Affecting Codons 557-558 of the c-KIT Gene Indicate a Poor Prognosis in Patients With Completely Resected Gastrointestinal Stromal Tumors: A Study by the Spanish Group for Sarcoma Research (GEIS)
2005
Protein Kinase C θ Is Highly Expressed in Gastrointestinal Stromal Tumors But Not in Other Mesenchymal Neoplasias
2004